Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-intensity Chemotherapy Combined With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
NCT07493161Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of venetoclax and inotuzumab ozogamicin in Acute lymphoblastic leukemia, Philadelphia chromosome positive (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Rate of BCR::ABL1 <=0.01% at 90 days and Modified Event-Free Survival up to 2 years. Started Apr 2026; status: recruiting.
02
Drugs
venetoclaxinotuzumab ozogamicin
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT07493161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493161.